A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
29 Jul, 2021
Authors: A Lugemwa, H Mujuru, B Wynne, A Violari, AR Kekitiinwa, CM Kity, M Archary, E Variava, T Sarfati, C Shakeshaft, R Turner, K Nathoo, E Chidziva, L Atwine, N…
Read More
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
29 Jul, 2021
Authors: C. Kityo, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali, A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M. Archary, M. Cotton, L.…
Read More
A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
21 Jul, 2021
Authors: LugemwaA, Mujuru H, Wynne B, Violari A, Kekitiinwa R.A, Kityo M.C, Archary M, Variava E, Sarfati T, Shakeshaft C, Turner R, Nathoo R, Chidziva E, Atwine L, Ramsagar N, Liberty…
Read More
Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial
21 Jul, 2021
Authors: Turkova A, Kekitiinwa A, White E, Mumbiro V, Khauda E, Liberty A, Dobbels E, Ahimbisibwe M.G, Moloantoa T, Atwine T, Kanjanavanit S, Mosia R.N, Puthanakit T, Smit T, Kobbe R,…
Read More
Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial
21 Jul, 2021
Authors: Turkova A, Kityo C, Mujuru A.H, Variava E, Kekitiinwa A, Lugemwa A, Barlow-Mosha L, Ngampiyaskul C, Zuidewind P, Puthanakit T, Mngqbisa R, Behuhuma O.N, Kataike H, Musoro G, Nandudu A,…
Read More
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
21 Jul, 2021
Authors: Kityo C, White E, Turkova A, Mujuru A.H, Nankya I, Wynne B, Ali S, Kekitiinwa A, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton M, Barlow-Mosha L,…
Read More
Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently
22 Mar, 2021
Authors: Chloe Lanyon, Janet Seeley, Stella Namukwaya, Victor Musiime, Sara Paparini, Helen Nakyambadde, Christine Matama, Anna Turkova, Sarah Bernays Published in: Journal of International Aids Society Abstract Introduction: Sustaining optimal adherence is the major challenge facing adolescents…
Read More
DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI- BASED ART IN CHILDREN AND ADOLESCENTS
11 Mar, 2021
Authors: Anna Turkova1, for the ODYSSEY/PENTA-20 Trial Team Published in: CROI 2021 Abstract: ODYSSEY is an international multi-centre randomised non-inferiority trial evaluating dolutegravir (DTG) + 2NRTIs versus standard-of-care (SOC)…
Read More
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
19 Feb, 2021
Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team Published in: BMC Infectious Diseases…
Read More
Pediatric dolutegravir (DTG) dosing recommendations derived from combined P1093 and ODYSSEY Population Pharmacokinetic analysis
04 Dec, 2020
Authors: Singh R, Baker M, Thapar M, Gibb D, Turkova A, Ford D, Ruel T, Wiznia A, Farhad M, Alvero C, Green J, Bollen P, Colbers A, Burger D, Acosta…
Read More
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
06 Aug, 2020
Authors: Bollen P, Moore CL , Mujuru H et al; the ODYSSEY trial team Published in: LANCET HIV. 2020;8:e533-e544 Background Paediatric dolutegravir doses approved by stringent regulatory authorities (SRAs) for…
Read More
Adeqaute dolutegravir exposure dosed BID with rifampicin in children 6 to < 18 years
13 Mar, 2020
Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E, Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and…
Read More
Adeqaute dolutegravir exposure dosed BID with rifampicin in children 6 to < 18 years
13 Mar, 2020
Authors: Waalewijn H, Mujuru HA, Amuge P, Cotton M, Bollen P, Chan M, Ali S, Variavan E,Makumbi S, Colbers A, Gibb D, Ford D, Burger D, Turkova A, and the…
Read More
Analysing small groups within clinical trials, while borrowing information from larger groups
14 Nov, 2019
Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A, White I, and ODYSSEY trial team Published in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019
Read More
Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to <20kg dosed using WHO weight bands
14 Sep, 2019
Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail Team Published in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019
Read More
Adult dolutegravir 50mg film-coated tablets in children living with HIV weighing 20 to <25 kg
14 Apr, 2019
Authors: Bollen P, Turkova A, Mujuru H, et al. for the ODYSSEY Trial Team Published in: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_830
Read More
Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing 14 to <25kg on film-coated dolutegravir 25mg tablets
14 Oct, 2018
Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22
Read More
ODYSSEY: design, current status, and baseline characteristics
14 Oct, 2018
Authors: Moore CL, Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34
Read More